Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone.
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
15 01 2020
15 01 2020
Historique:
received:
25
08
2019
revised:
01
10
2019
accepted:
02
10
2019
pubmed:
20
11
2019
medline:
23
4
2020
entrez:
20
11
2019
Statut:
ppublish
Résumé
Role of omega-3-Fatty acids, especially eicosapentaenoic acid (EPA), in reducing cardiovascular events is not clear. We conducted a meta-analysis including trial sequential analysis (TSA) of all available randomized controlled trials (RCTs) assessing the impact of EPA + statin on cardiovascular risk reduction. The aim is to appraise cardiovascular risk reduction with EPA and statin taken together. A comprehensive search of PubMed and EMBASE databases was conducted for all RCTs that compared EPA + Statin versus statin alone and included outcomes related to cardiovascular health. We calculated a comprehensive odds ratio (ORs) and 95% confidence intervals (CIs) using a random-effects model. We included 5 RCTs totaling 27,415 patients. Our results demonstrated that EPA + statin resulted in 18% reduction in the incidence of MACE (OR = 0.78; 95% CI: 0.65 to 0.93, I
Identifiants
pubmed: 31740020
pii: S0002-9149(19)31155-5
doi: 10.1016/j.amjcard.2019.10.009
pii:
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Eicosapentaenoic Acid
AAN7QOV9EA
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
198-204Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.